HUE069012T2 - Szepiapterin és metabolitjainak alkalmazása sugárzásnak való kitettség kezelésére - Google Patents

Szepiapterin és metabolitjainak alkalmazása sugárzásnak való kitettség kezelésére

Info

Publication number
HUE069012T2
HUE069012T2 HUE20758407A HUE20758407A HUE069012T2 HU E069012 T2 HUE069012 T2 HU E069012T2 HU E20758407 A HUE20758407 A HU E20758407A HU E20758407 A HUE20758407 A HU E20758407A HU E069012 T2 HUE069012 T2 HU E069012T2
Authority
HU
Hungary
Prior art keywords
sepiapterin
metabolites
radiation exposure
treat radiation
treat
Prior art date
Application number
HUE20758407A
Other languages
English (en)
Hungarian (hu)
Inventor
Eleonora Mezzaroma
Christopher Rabender
Ross Mikkelsen
Vasily Yakovlev
Neil Smith
Original Assignee
Ptc Therapeutics Mp Inc
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Mp Inc, Univ Virginia Commonwealth filed Critical Ptc Therapeutics Mp Inc
Publication of HUE069012T2 publication Critical patent/HUE069012T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
HUE20758407A 2019-08-05 2020-08-05 Szepiapterin és metabolitjainak alkalmazása sugárzásnak való kitettség kezelésére HUE069012T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962882937P 2019-08-05 2019-08-05

Publications (1)

Publication Number Publication Date
HUE069012T2 true HUE069012T2 (hu) 2025-02-28

Family

ID=72148243

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE20758407A HUE069012T2 (hu) 2019-08-05 2020-08-05 Szepiapterin és metabolitjainak alkalmazása sugárzásnak való kitettség kezelésére

Country Status (21)

Country Link
US (1) US20220273661A1 (https=)
EP (2) EP4454712A3 (https=)
JP (2) JP7642611B2 (https=)
CN (2) CN119837879A (https=)
AU (1) AU2020324435B2 (https=)
BR (1) BR112022002029A2 (https=)
CA (1) CA3146477A1 (https=)
DK (1) DK4009978T3 (https=)
ES (1) ES2994060T3 (https=)
FI (1) FI4009978T3 (https=)
HR (1) HRP20241653T1 (https=)
HU (1) HUE069012T2 (https=)
IL (1) IL290321B1 (https=)
LT (1) LT4009978T (https=)
MX (1) MX2022001535A (https=)
PL (1) PL4009978T3 (https=)
PT (1) PT4009978T (https=)
RS (1) RS66096B1 (https=)
SI (1) SI4009978T1 (https=)
SM (1) SMT202500089T1 (https=)
WO (1) WO2021026247A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
EP3801536B1 (en) 2018-05-30 2024-07-17 PTC Therapeutics MP, Inc. Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
CN112654356A (zh) 2018-05-30 2021-04-13 Ptc医疗Mp公司 增加四氢生物蝶呤血浆暴露的组合物和方法
IL290321B1 (en) * 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
EP1696877A4 (en) 2003-11-13 2010-06-09 Gen Hospital Corp PROCESS FOR PAIN TREATMENT
WO2006055511A2 (en) 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
TWI359019B (en) * 2006-08-14 2012-03-01 Merck Eprova Ag Use of folates for the prevention and treatment of
KR20160068776A (ko) 2013-09-13 2016-06-15 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 방사선 효과의 완화 및 예방을 위한 조성물의 제조 및 용도
WO2016054458A1 (en) 2014-10-02 2016-04-07 Cytosorbents Corporation Use of gastroinstestinally administered porous enteron sorbent polymers to prevent or treat radiation induced mucositis, esophagitis, enteritis, colitis, and gastrointestinal acute radiation syndrome
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
IL290321B1 (en) * 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
CN110354133A (zh) * 2019-08-26 2019-10-22 鞍山市肿瘤医院 四氢生物蝶呤的应用及药物

Also Published As

Publication number Publication date
AU2020324435B2 (en) 2026-03-19
IL290321B1 (en) 2026-04-01
PT4009978T (pt) 2024-11-05
RS66096B1 (sr) 2024-11-29
CA3146477A1 (en) 2021-02-11
EP4009978B1 (en) 2024-09-25
EP4454712A2 (en) 2024-10-30
EP4454712A3 (en) 2025-01-01
SMT202500089T1 (it) 2025-03-12
IL290321A (en) 2022-04-01
CN119837879A (zh) 2025-04-18
MX2022001535A (es) 2022-03-04
PL4009978T3 (pl) 2025-02-24
JP2022543655A (ja) 2022-10-13
FI4009978T3 (fi) 2024-11-01
ES2994060T3 (en) 2025-01-16
AU2020324435A1 (en) 2022-02-24
DK4009978T3 (da) 2024-10-14
US20220273661A1 (en) 2022-09-01
WO2021026247A1 (en) 2021-02-11
LT4009978T (lt) 2024-11-25
HRP20241653T1 (hr) 2025-04-25
JP2025098011A (ja) 2025-07-01
BR112022002029A2 (pt) 2022-06-07
SI4009978T1 (sl) 2025-03-31
CN114555090A (zh) 2022-05-27
EP4009978A1 (en) 2022-06-15
CN114555090B (zh) 2024-12-17
JP7642611B2 (ja) 2025-03-10

Similar Documents

Publication Publication Date Title
LT4009978T (lt) Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
IL292810A (en) Therapeutic compounds and methods of use
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
IL278978A (en) Preparations and methods for treating eczema
IL280000A (en) Formulations for reducing tumors and methods of using them
EP3692973A4 (en) BACK SUPPORT FOR ANKLE SPHAT, AND ANKLE SPHAT
EP3749700B8 (de) Mit aktinischer strahlung fixierbare masse und ihre verwendung
GB2589398B (en) Compounds and methods of use
SG11202011454TA (en) Ex-vivo model of inflamed human skin and uses thereof for screening anti-inflammatory compounds
IL283061A (en) Use of dantrolene and dantrolene prodrugs to treat radiation exposure
IL274433A (en) Fulvestrant formulations and methods of using them
IL272847B1 (en) Methods of using dantrolene to treat nerve gas exposure
SG11202009795PA (en) Protection of biologically active molecules during radiation sterilization
ZA202100752B (en) Treatment and prevention of injury due to radiation exposure
HK40060691A (en) Use of dantrolene and dantrolene prodrugs to treat radiation exposure
ZA202104656B (en) Deuterated forms and derivatives of volinanserin
IL282566A (en) Synthesis of (S)-6-hydroxytryptophan and their derivatives
IL278575B1 (en) Dantrolene formulations and methods of using them
GB201908573D0 (en) Compounds and methods of use
IL283912A (en) Methods for treating cancer using the platenoside molecule and its isomers
IL277988A (en) Compounds and methods for treating demyelination
HK40051014A (en) Methods and compositions for treating chronic effects of radiation and chemical exposure
HK40042340A (en) Using power loss density and related measures to quantify the dose of tumor treating fields (ttfields)
GB201815000D0 (en) Treatment of hypothroidism and related conditions
GB201809005D0 (en) Compositions and methods realting to the treatment of psoriasis